Thrasos Therapeutics Issued U.S. Patent for First-in-Class Compounds That Selectively Target Key Receptors of the Bone Morphogenetic Protein Pathway

HOPKINTON, Mass.--(BUSINESS WIRE)--Thrasos Therapeutics, Inc., a biotechnology company developing unique therapeutic agents to treat severe organ failure and other critical medical needs, announced today the issuance of U.S. patent number 7,482,329 covering a proprietary set of small molecules that selectively activate key receptors of the bone morphogenetic protein (BMP) family. These compounds selectively activate the repair and regenerative effects of BMP without stimulating bone growth. This key differentiating factor offers significant potential for treating a broad range of life-threatening diseases and conditions, including Acute Kidney Injury (AKI) and Chronic Kidney Disease (CKD), the initial focus areas of the Company.